Harvard Bioscience (HBIO) Competitors

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.

Which has better valuation and earnings, TMO or HBIO?

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$42.90B	3.66	$6.34B	$17.05	24.42
Harvard Bioscience	$91.40M	0.25	-$3.41M	-$1.32	-0.40

Does the MarketBeat Community prefer TMO or HBIO?

Thermo Fisher Scientific received 722 more outperform votes than Harvard Bioscience when rated by MarketBeat users. Likewise, 80.71% of users gave Thermo Fisher Scientific an outperform vote while only 71.02% of users gave Harvard Bioscience an outperform vote.

Company	Underperform	Outperform
Thermo Fisher Scientific	Outperform Votes 1092 80.71%	Underperform Votes 261 19.29%
Harvard Bioscience	Outperform Votes 370 71.02%	Underperform Votes 151 28.98%

Is TMO or HBIO more profitable?

Thermo Fisher Scientific has a net margin of 14.78% compared to Harvard Bioscience's net margin of -14.57%. Thermo Fisher Scientific's return on equity of 17.51% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	14.78%	17.51%	8.52%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Do insiders and institutionals hold more shares of TMO or HBIO?

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 9.5% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts recommend TMO or HBIO?

Thermo Fisher Scientific currently has a consensus target price of $605.30, suggesting a potential upside of 45.39%. Harvard Bioscience has a consensus target price of $3.00, suggesting a potential upside of 474.71%. Given Harvard Bioscience's higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.80
Harvard Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer TMO or HBIO?

In the previous week, Thermo Fisher Scientific had 19 more articles in the media than Harvard Bioscience. MarketBeat recorded 46 mentions for Thermo Fisher Scientific and 27 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.48 beat Harvard Bioscience's score of -0.20 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	40 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more risk & volatility, TMO or HBIO?

Thermo Fisher Scientific has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 15 of the 18 factors compared between the two stocks.